Menarini Group and NewAmsterdam Pharma Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
- First-in-Class approval supported by Phase 3 BROADWAY, BROOKLYN, and TANDEM trials demonstrating significant LDL-C reductions with favorable tolerability profile - - First global regulatory approval of obicetrapib marks a defining milestone for NewAmsterdam and Menarini, expanding...
Short extract only — this publisher licenses its text. Read the full release at the source.
More from Commercial newswire
- Veeva lance le Falcon Router pour le triage agentique de tous les canaux de reporting
- HelloNation Examines Custom Engagement Rings Vs Ready-Made Engagement Rings With Jewelry Expert Sergio Palazzo
- Prospect HQ Launches iOS App, Expanding Career Network for Student-Athletes
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
7 days, no card required.
Read releases like this the second they cross the wire.
1,200+ — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →